PharVision Advisers’s Mastercard MA Stock Holding History

PharVision Advisers’s Portfolio MA Stock Details MA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-618	Closed	-$352K	–	874
2025 Q3	$352K	Buy	+618	New	+$355K	0.2%	139

Other funds holding MA

JSC

J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mastercard Foundation Asset Management (MFAM) Toronto, Ontario, Canada $33.7B AUM 8.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

PharVision Advisers's MA Position: Q4 2025 in Review

PharVision Advisers sold out of Mastercard (MA) in Q4 2025, closing a stake of 618 shares — an estimated $352K sold.

PharVision Advisers first reported a position in MA in Q3 2025 and held it in 1 quarter. The position peaked at $352K in Q3 2025. 3,723 funds tracked by Wall St. Rank hold MA as of Q4 2025.

PharVision Advisers reported no remaining Mastercard position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 618 Mastercard shares in Q4 2025, an estimated $352K.
PharVision Advisers first reported a position in Mastercard in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Mastercard position peaked at $352K in Q3 2025.
3,723 funds tracked by Wall St. Rank held Mastercard as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.